血栓症治療薬市場：薬剤クラス別、疾患タイプ別、流通チャネル別-2025-2030年の世界予測

血栓症治療薬市場は、2023年に289億3,000万米ドルと評価され、2024年には306億米ドルに達すると予測され、CAGR 5.84％で成長し、2030年には430億6,000万米ドルに達すると予測されています。

血栓症治療薬市場には、深部静脈血栓症（DVT）、肺塞栓症（PE）、脳卒中などの症状を引き起こす血管内の血栓の予防と治療に使用される医薬品が含まれます。血栓症治療薬は、特に手術を受ける患者や心房細動のある患者、血栓形成のリスクが高い患者など、臨床現場において極めて重要です。適用範囲は、病院、専門クリニック、在宅ケアなど複数のヘルスケア環境にまたがり、エンドユーザーは医療従事者と患者です。市場の成長は主に、心血管疾患の有病率の増加、人口の高齢化、血栓症疾患に対する意識の高まりによってもたらされます。さらに、経口抗凝固薬や標的治療薬などのドラッグデリバリーシステムの進歩も、大きな成長要因となっています。個別化医療のアプローチや生物製剤の革新に新たなビジネスチャンスがあり、副作用を効果的に軽減して治療成果を高めることができます。しかし、市場拡大の妨げとなっているのは、厳しい規制の枠組み、高い開発コスト、薬剤の承認と価格設定に立ちはだかる特許の崖などの要因です。さらに、抗凝固剤に伴う出血リスクなどの合併症が制約となっています。このような課題にもかかわらず、特に安全性の高い次世代抗凝固薬の開発や、より良い患者層別化のためのAI主導型診断の統合など、市場にはイノベーションの大きな可能性があります。包括的な患者データを活用して現実世界のエビデンスに情報を提供し、ヘルスケア・インフラが急成長している未開拓市場に進出することで、成長を後押しすることができます。バイオテクノロジー企業との提携や新規薬剤メカニズムに焦点を当てた研究開発への投資も、市場の障壁を克服する上で重要な役割を果たします。全体として、血栓症治療薬市場はダイナミックであり、より安全で効果的な治療オプションに向けた研究開発の余地は大きいです。

市場力学：急速に進化する血栓症治療薬市場の主要市場インサイトを公開

血栓症治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 血栓症治療に対する患者の意識の高まり
  • 腎臓病、脳卒中、高血圧の有病率の急増
  • 医薬品に対する有利な償還シナリオ
• 市場抑制要因
  • 医薬品と治療費の高騰
• 市場機会
  • 治療技術の進歩と小売薬局の増加
  • ヘルスケア支出の増加と共同活動の増加
• 市場の課題
  • 厳しい医薬品規制制度

ポーターの5つの力：血栓症治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することで、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：血栓症治療薬市場における外部からの影響の把握

外部マクロ環境要因は、血栓症治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析血栓症治療薬市場における競合情勢の把握

血栓症治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス血栓症治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、血栓症治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨血栓症治療薬市場における成功への道筋を描く

血栓症治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 血栓症治療に関する患者の意識の高まり
    • 腎臓病、脳卒中、高血圧の罹患率の急増
    • 薬剤の有利な償還シナリオ
  • 抑制要因
    • 薬と治療の高額な費用
  • 機会
    • 治療における技術の進歩と小売薬局の増加
    • ヘルスケア費の増加と共同活動の増加
  • 課題
    • 厳格な薬物規制システム
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 血栓症治療薬市場薬剤クラス別

• 因子Xa阻害剤
• ヘパリン
• P2Y12血小板阻害剤

第7章 血栓症治療薬市場：疾患タイプ別

• 心房細動
• 深部静脈血栓症
• 肺塞栓症

第8章 血栓症治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第9章 南北アメリカの血栓症治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の血栓症治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの血栓症治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Aspen Pharmacare Holdings Limited by Mylan N.V.
• Aurobindo Pharmaceuticals USA, Inc.
• B. Braun Melsungen AG
• Bayer AG
• Becton, Dickinson and Company
• Boehringer Ingelheim GmbH
• Bristol-Myers Squibb
• Cardinal Health, Inc.
• GoodRx Holdings, Inc.
• Grifols, S.A
• Inari Medical, Inc.
• ITALFARMACO S.p.A
• Johnson & Johnson Services, Inc.
• Pfizer, Inc
• Sanofi S.A.

LIST OF FIGURES

• FIGURE 1. THROMBOSIS DRUG MARKET RESEARCH PROCESS
• FIGURE 2. THROMBOSIS DRUG MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL THROMBOSIS DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. THROMBOSIS DRUG MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. THROMBOSIS DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. THROMBOSIS DRUG MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL THROMBOSIS DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. THROMBOSIS DRUG MARKET DYNAMICS
• TABLE 7. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY FACTOR XA INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY HEPARIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY P2Y12 PLATELET INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ATRIAL FIBRILLATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL THROMBOSIS DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 23. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 26. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 29. CANADA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 30. CANADA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 32. MEXICO THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES THROMBOSIS DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 39. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 43. AUSTRALIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 46. CHINA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 47. CHINA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 49. INDIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 50. INDIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 52. INDONESIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. JAPAN THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. MALAYSIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. PHILIPPINES THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. SINGAPORE THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. SOUTH KOREA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. TAIWAN THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. THAILAND THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. VIETNAM THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA THROMBOSIS DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 83. DENMARK THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 86. EGYPT THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 89. FINLAND THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 92. FRANCE THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. GERMANY THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. ISRAEL THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. ITALY THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 102. ITALY THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. NIGERIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. NORWAY THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. POLAND THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 114. POLAND THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. QATAR THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 117. QATAR THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. SPAIN THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. SWEDEN THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. SWITZERLAND THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. TURKEY THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM THROMBOSIS DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. THROMBOSIS DRUG MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 147. THROMBOSIS DRUG MARKET, FPNV POSITIONING MATRIX, 2023

The Thrombosis Drug Market was valued at USD 28.93 billion in 2023, expected to reach USD 30.60 billion in 2024, and is projected to grow at a CAGR of 5.84%, to USD 43.06 billion by 2030.

The thrombosis drug market encompasses medications used for the prevention and treatment of blood clots within blood vessels, which can lead to conditions such as deep vein thrombosis (DVT), pulmonary embolism (PE), and strokes. Thrombosis drugs are crucial in clinical settings, especially for patients undergoing surgeries, with atrial fibrillation, or those at high risk of clot formation. The application scope spans multiple healthcare settings, including hospitals, specialized clinics, and homecare settings, with end-users comprising healthcare professionals and patients. The market's growth is primarily driven by the increasing prevalence of cardiovascular diseases, an aging population, and heightened awareness of thrombosis disorders. Additionally, advancements in drug delivery systems, such as oral anticoagulants and targeted therapies, are significant growth influencers. Emerging opportunities lie in personalized medicine approaches and innovations in biologics, effectively reducing side effects and enhancing therapeutic outcomes. However, market expansion is hindered by factors such as stringent regulatory frameworks, high developmental costs, and patent cliffs challenging drug approvals and pricing. Furthermore, complications such as bleeding risks associated with anticoagulants pose limitations. Despite these challenges, the market offers substantial potential for innovation, particularly in developing safer, next-generation anticoagulants and integrating AI-driven diagnostics for better patient stratification. Leveraging comprehensive patient data to inform real-world evidence and expanding into underserved markets with burgeoning healthcare infrastructure can bolster growth. Collaborations with biotechnology firms and investments in R&D focusing on novel drug mechanisms can also play crucial roles in overcoming market barriers. Overall, the thrombosis drugs market is dynamic, with enormous scope for research and development directed toward safer and more effective therapeutic options.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Thrombosis Drug Market

The Thrombosis Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing patient awareness regarding thrombosis treatment
  • Surge in prevalence of kidney diseases, stroke, and hypertension
  • Favorable reimbursement scenario for the drugs
• Market Restraints
  • High cost of the medicines and treatment
• Market Opportunities
  • Technological advancements in the treatment and increasing number of retail pharmacies
  • Growing healthcare expenditure and rise of collaborative activities
• Market Challenges
  • Strict drug regulatory systems

Porter's Five Forces: A Strategic Tool for Navigating the Thrombosis Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Thrombosis Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Thrombosis Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Thrombosis Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Thrombosis Drug Market

A detailed market share analysis in the Thrombosis Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Thrombosis Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Thrombosis Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Thrombosis Drug Market

A strategic analysis of the Thrombosis Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Thrombosis Drug Market, highlighting leading vendors and their innovative profiles. These include Aspen Pharmacare Holdings Limited by Mylan N.V., Aurobindo Pharmaceuticals USA, Inc., B. Braun Melsungen AG, Bayer AG, Becton, Dickinson and Company, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Cardinal Health, Inc., GoodRx Holdings, Inc., Grifols, S.A, Inari Medical, Inc., ITALFARMACO S.p.A, Johnson & Johnson Services, Inc., Pfizer, Inc, and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Thrombosis Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Drug Class, market is studied across Factor Xa Inhibitor, Heparin, and P2Y12 Platelet Inhibitor.
• Based on Disease Type, market is studied across Atrial Fibrillation, Deep Vein Thrombosis, and Pulmonary Embolism.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing patient awareness regarding thrombosis treatment
    • 5.1.1.2. Surge in prevalence of kidney diseases, stroke, and hypertension
    • 5.1.1.3. Favorable reimbursement scenario for the drugs
  • 5.1.2. Restraints
    • 5.1.2.1. High cost of the medicines and treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements in the treatment and increasing number of retail pharmacies
    • 5.1.3.2. Growing healthcare expenditure and rise of collaborative activities
  • 5.1.4. Challenges
    • 5.1.4.1. Strict drug regulatory systems
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Thrombosis Drug Market, by Drug Class

• 6.1. Introduction
• 6.2. Factor Xa Inhibitor
• 6.3. Heparin
• 6.4. P2Y12 Platelet Inhibitor

7. Thrombosis Drug Market, by Disease Type

• 7.1. Introduction
• 7.2. Atrial Fibrillation
• 7.3. Deep Vein Thrombosis
• 7.4. Pulmonary Embolism

8. Thrombosis Drug Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas Thrombosis Drug Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Thrombosis Drug Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Thrombosis Drug Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Aspen Pharmacare Holdings Limited by Mylan N.V.
• 2. Aurobindo Pharmaceuticals USA, Inc.
• 3. B. Braun Melsungen AG
• 4. Bayer AG
• 5. Becton, Dickinson and Company
• 6. Boehringer Ingelheim GmbH
• 7. Bristol-Myers Squibb
• 8. Cardinal Health, Inc.
• 9. GoodRx Holdings, Inc.
• 10. Grifols, S.A
• 11. Inari Medical, Inc.
• 12. ITALFARMACO S.p.A
• 13. Johnson & Johnson Services, Inc.
• 14. Pfizer, Inc
• 15. Sanofi S.A.